Physiological hydrated alginate hydrogel for assistant heart failure treatment and preparation method thereof

Abstract

The invention relates to physiological hydrated alginate hydrogel for assistant heart failure treatment. The hydrogel is prepared from a sodium alginate system and a calcium alginate system, wherein the volume ratio of the sodium alginate system to the calcium alginate system is 7:9-9:7; after the sodium alginate system and the calcium alginate system are mixed, the concentration of sodions in the hydrogel is c mmol / L, wherein 140<c<160. The invention further provides a preparation method of the alginate hydrogel. The physiological hydrated alginate hydrogel with the sodions within a range of 140-160 mmol / L is obtained by crosslinking the sodium alginate system to the calcium alginate system and can achieve the functions of biocompatibility, long-term replacement and biological tissue simulation in a physiological environment. The alginate hydrogel can be directly injected into the ventricular wall, fill and simulate the cardiac muscles to be a part of the ventricular wall and reach osmotic balance with contacted cardiac muscle cells to ensure that the mechanical property of the alginate hydrogel cannot be changed and the alginate hydrogel cannot harm the cardiac muscle cells.

Description

technical field [0001] The present invention relates to the field of alginate hydrogel, in particular to a physiologically hydrated alginate hydrogel for auxiliary treatment of heart failure and a preparation method thereof Background technique [0002] Heart failure, referred to as heart failure, refers to cardiac circulation disorders caused by cardiac systolic and diastolic dysfunction, venous return blood cannot fully discharge the heart, resulting in blood stasis in the venous system and insufficient blood perfusion in the arterial system. One of the main manifestations of the deterioration and pathological remodeling of heart failure is the change of left ventricular shape and structure, such as ventricular dilatation, hypertrophy, and spherical enlargement, which further aggravate the deterioration of patients' clinical symptoms. For patients with heart failure, the current treatment options for heart failure are very limited. Drug therapy is a relatively mild standar...

AI Technical Summary

Problems solved by technology

For patients with heart failure, the current treatment options for heart failure are very limited. Drug therapy is a relatively mild standard strategy for the treatment of heart failure, but it cannot curb the continuous decline of left ventricular function; cardioverter-defibrillator (ICD), Physiotherapy methods such as cardiac resynchronization therapy (CRT) have factors such as high price and short duration of curative effect; and the final heart transplantation has limitations such as limited donor sources, high surgical risks, and various clinical complications, making it difficult to popularization

Images